Giovanni López
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Giovanni López has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Mieke Vandamme
Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Institute for the Future, KU Leuven, Leuven, Belgium
2 shared publications - Bernardo Galvão-Castro
Advanced Laboratory of Public Health, Gonçalo Moniz Center, Fundação Oswaldo Cruz, Salvador, Bahia Brazil ; Bahian School of Medicine and Public Health (EBMSP), Salvador, Bahia Brazil
2 shared publications - Eduardo Gotuzzo
Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru
2 shared publications - Johan Van Weyenbergh
KU Leuven
2 shared publications - Michael Talledo
Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru
2 shared publications - Ricardo Khouri
Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Rua Waldemar Falcão, 121, Candeal, Salvador 40296-710, Bahia, Brazil
2 shared publications
Latest Publications
- Open Access
- 29 January 2014
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 11 (1) , 18
CD80+ and CD86+B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis
Background: Human T-cell lymphotropic virus (HTLV-1) is the causative agent of the incapacitating, neuroinflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Currently, there are no disease-modifying therapies with long-term clinical benefits or validated biomarkers for clinical follow-up in HAM/TSP. Although CD80 and CD86 costimulatory molecules play prominent roles in immune regulation and reflect disease status in multiple sclerosis (MS), data in HAM/TSP are lacking.Methods: Using flow cytometry, we quantifiedex vivoandin vitroexpression of CD80 and CD86 in PBMCs of healthy controls, HTLV-1-infected individuals with and without HAM/TSP, and MS patients. We hypothesizedex vivoCD80 and CD86 expressions and theirin vitroregulation by interferon (IFN)-α/β mirror similarities between HAM/TSP and MS and hence might reveal clinically useful biomarkers in HAM/TSP.Results: Ex vivoexpression of CD80 and CD86 in T and B cells increased in all HTLV-1 infected individuals, but with a selective defect for B cell CD86 upregulation in HAM/TSP. Despite decreased total B cells with increasing disease duration (p = 0.0003,r = −0.72), CD80+B cells positively correlated with disease severity (p = 0.0017,r = 0.69) in HAM/TSP. B cell CD80 expression was higher in women with HAM/TSP, underscoring that immune markers can reflect the female predominance observed in most autoimmune diseases. In contrast to MS patients, CD80+(p = 0.0001) and CD86+(p = 0.0054) lymphocytes expanded uponin vitroculture in HAM/TSP patients. The expansion of CD80+and CD86+T cells but not B cells was associated with increased proliferation in HTLV-1 infection.In vitrotreatment with IFN-β but not IFN-α resulted in a pronounced increase of B cell CD86 expression in healthy controls, as well as in patients with neuroinflammatory disease (HAM/TSP and MS), similar toin vivotreatment in MS.Conclusions: We propose two novel biomarkers,ex vivoCD80+B cells positively correlating to disease severity and CD86+B cells preferentially induced by IFN-β, which restores defective upregulation in HAM/TSP. This study suggests a role for B cells in HAM/TSP pathogenesis and opens avenues to B cell targeting (with proven clinical benefit in MS) in HAM/TSP but also CD80-directed immunotherapy, unprecedented in both HAM/TSP and MS.
- 29 January 2014
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 11 (1) , 18
Open AccessCD80+ and CD86+B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis
Background: Human T-cell lymphotropic virus (HTLV-1) is the causative agent of the incapacitating, neuroinflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Currently, there are no disease-modifying therapies with long-term clinical benefits or validated biomarkers for clinical follow-up in HAM/TSP. Although CD80 and CD86 costimulatory molecules play prominent roles in immune regulation and reflect disease status in multiple sclerosis (MS), data in HAM/TSP are lacking.Methods: Using flow cytometry, we quantifiedex vivoandin vitroexpression of CD80 and CD86 in PBMCs of healthy controls, HTLV-1-infected individuals with and without HAM/TSP, and MS patients. We hypothesizedex vivoCD80 and CD86 expressions and theirin vitroregulation by interferon (IFN)-α/β mirror similarities between HAM/TSP and MS and hence might reveal clinically useful biomarkers in HAM/TSP.Results: Ex vivoexpression of CD80 and CD86 in T and B cells increased in all HTLV-1 infected individuals, but with a selective defect for B cell CD86 upregulation in HAM/TSP. Despite decreased total B cells with increasing disease duration (p = 0.0003,r = −0.72), CD80+B cells positively correlated with disease severity (p = 0.0017,r = 0.69) in HAM/TSP. B cell CD80 expression was higher in women with HAM/TSP, underscoring that immune markers can reflect the female predominance observed in most autoimmune diseases. In contrast to MS patients, CD80+(p = 0.0001) and CD86+(p = 0.0054) lymphocytes expanded uponin vitroculture in HAM/TSP patients. The expansion of CD80+and CD86+T cells but not B cells was associated with increased proliferation in HTLV-1 infection.In vitrotreatment with IFN-β but not IFN-α resulted in a pronounced increase of B cell CD86 expression in healthy controls, as well as in patients with neuroinflammatory disease (HAM/TSP and MS), similar toin vivotreatment in MS.Conclusions: We propose two novel biomarkers,ex vivoCD80+B cells positively correlating to disease severity and CD86+B cells preferentially induced by IFN-β, which restores defective upregulation in HAM/TSP. This study suggests a role for B cells in HAM/TSP pathogenesis and opens avenues to B cell targeting (with proven clinical benefit in MS) in HAM/TSP but also CD80-directed immunotherapy, unprecedented in both HAM/TSP and MS.
- Open Access
- 23 August 2012
- Published by Springer Nature in Virology Journal
- Vol. 9 (1) , 171
Simultaneous RNA quantification of human and retroviral genomes reveals intact interferon signaling in HTLV-1-infected CD4+ T cell lines
IFN-α contributes extensively to host immune response upon viral infection through antiviral, pro-apoptotic, antiproliferative and immunomodulatory activities. Although extensively documented in various types of human cancers and viral infections, controversy exists in the exact mechanism of action of IFN-α in human immunodeficiency virus type 1 (HIV-1) and human T-lymphotropic virus type 1 (HTLV-1) retroviral infections.
- 23 August 2012
- Published by Springer Nature in Virology Journal
- Vol. 9 (1) , 171
Open AccessSimultaneous RNA quantification of human and retroviral genomes reveals intact interferon signaling in HTLV-1-infected CD4+ T cell lines
IFN-α contributes extensively to host immune response upon viral infection through antiviral, pro-apoptotic, antiproliferative and immunomodulatory activities. Although extensively documented in various types of human cancers and viral infections, controversy exists in the exact mechanism of action of IFN-α in human immunodeficiency virus type 1 (HIV-1) and human T-lymphotropic virus type 1 (HTLV-1) retroviral infections.
- Open Access
- 6 June 2011
- Published by Springer Nature in Retrovirology
- Vol. 8 (S1) , A253-1
Proviral load does not discriminate patients with Human T-Cell Leukemia/Lymphoma (ATLL) from HTLV-1 carriers with a history of Strongyloidiasis
- 6 June 2011
- Published by Springer Nature in Retrovirology
- Vol. 8 (S1) , A253-1
Open AccessProviral load does not discriminate patients with Human T-Cell Leukemia/Lymphoma (ATLL) from HTLV-1 carriers with a history of Strongyloidiasis